Industry Supported Sessions Programs

Industry Supported Sessions Programs

THURSDAY, MARCH 28, 2019

INDUSTRY SESSION 3

DETECTING AD AND PD WITH PLASMA BIOMARKERS: INNOVATIONS THAT INFORM CLINICAL PRACTICE

SYMPOSIUM IS ORGANISED AND SUPPORTED BY MagQu Co. Ltd. 

Thursday, March 28| 09:15 - 11:15 | Auditorium I

Chair: Kaj Blennow (Sweden)      

09:15–09:20   INTRODUCTIONS AND MEETING OBJECTIVES
                      Kaj Blennow (Sweden)

09:20–09:35   PLASMA BIOMARKERS FOR AD: THE CURRENT LANDSCAPE
                      Harald Hampel (France)

09:35–09:50   THE IMR-SQUID TECHNOLOGY PLATFORM
                      Shieh-Yueh Yang (Taiwan)

09:50–10:10   GLOBAL VALIDATION OF THE IMR ASSAY IN AD
                      Lih-Fen Lue (USA)

10:10–10:30   CORRELATION OF THE IMR ASSAY WITH IMAGING BIOMARKERS (MRI & PET)
                      Ming-Jang Chiu (Taiwan)

10:30-10:50   DIFFERENTIAL DIAGNOSIS OF THE IMR ASSAY IN AD, PD, & FTD
                      Chin-Hsien Lin (Taiwan)

10:50-11:05   HOW PLASMA BIOMARKERS MAY INFORM CLINICAL PRACTICE
                      José Luis Molinuevo (Spain)

11:05-11:15   Q&A SESSION
                      Kaj Blennow (Sweden)

FRIDAY, MARCH 29, 2019


INDUSTRY SESSION 11: 

FROM MICE TO MEN: INCREASING PREDICTIVE VALUE IN CNS DRUG DEVELOPMENT

SYMPOSIUM IS ORGANISED AND SUPPORTED BY PsychoGenics / NeuroScios 

Friday, March 29| 17:15 - 19:15 | Auditorium VI+VII

Chairs:  Manfred Windisch (AUSTRIA) and Emer Leahy (USA)         


17:15–17:35    NEXT-GENERATION MOUSE MODELS OF ALZHEIMER'S DISEASE

Gregory Carter (USA)

 

17:35–17:55    HIGH CONTENT PHENOTYPING AND MACHINE LEARNING APPROACHES TO AD DRUG DISCOVERY

Emer Leahy (USA)


17:55–18:15    INSIGHTS INTO ALTERED CNS FUNCTION BY EEG BIOMARKERS: APPLICATION TO AD DRUG DISCOVERY
Steve Leiser (USA)

 

18:15–18:35    LINKING EXPERIMENTAL MODELS OF AD TO PRECLINICAL AND CLINICAL DRUG                        DEVELOPMENT PROGRAMS

                        Eliezer Masliah (USA)

 

18:35–18:55    ADVANCED MEDICAL IMAGE HANDLING AND ANALYSIS IN CNS CLINICAL TRIALS
Matt Rowe (UK)

 

18:55-19:15     DRUG DEVELOPMENT IN AD - CHALLENGES IN CLINIC AND BEHAVIORAL TESTING
Jakub Hort (CZECH REPUBLIC)